.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
Cerilliant
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Chinese Patent Office
US Army
Colorcon
Julphar

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,632,517

« Back to Dashboard

Which drugs does patent 7,632,517 protect, and when does it expire?


Patent 7,632,517 protects ZOLPIMIST and is included in one NDA.

This patent has eighty-eight patent family members in ten countries.

Summary for Patent: 7,632,517

Title:Buccal, polar and non-polar spray containing zolpidem
Abstract:Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.
Inventor(s): Dugger, III; Harry A. (Flemington, NJ), Abd El-Shafy; Mohammed (Hauppauge, NY)
Assignee: Novadel Pharma Inc. (Flemington, NJ)
Application Number:10/671,715
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008RXYesYes► Subscribe► Subscribe TREATMENT OF TRANSIENT INSOMNIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,632,517

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,676,931 Buccal, polar and non-polar spray or capsule► Subscribe
6,998,110Buccal, polar and non-polar spray or capsule► Subscribe
8,236,285Buccal, polar and non-polar spray containing zolpidem► Subscribe
9,078,816Buccal, polar and non-polar spray containing ondansetron► Subscribe
6,977,070 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system► Subscribe
6,969,508 Buccal, polar and non-polar spray or capsule containing drugs for treating pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,632,517

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand539285► Subscribe
New Zealand561128► Subscribe
Canada2581996► Subscribe
Canada2582007► Subscribe
Canada2582008► Subscribe
Canada2582018► Subscribe
Canada2582265► Subscribe
Germany69738333► Subscribe
European Patent Office1019019► Subscribe
European Patent Office1029536► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
McKinsey
Healthtrust
Harvard Business School
Daiichi Sankyo
Medtronic
Chubb
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot